Avantor (NYSE:AVTR) saw its shares jump 14.8% to $14.26 in regular trading on July 29, 2026, after the company reported second-quarter revenue and adjusted earnings that exceeded analysts' expectations. The laboratory-supplies group also raised its full-year organic-sales guidance, fueling investor optimism.
Quarterly revenue reached $1.692 billion, surpassing the preliminary FactSet consensus of $1.61 billion by approximately $82 million. Adjusted earnings per share came in at $0.21, topping the $0.19 estimate, though down from $0.24 in the same period last year. The company's organic-sales midpoint improved by 150 basis points to flat, while adjusted EPS midpoint rose only 1.9%.
Despite the positive revenue surprise, margin and cash-flow targets remained unchanged. Management kept its adjusted EBITDA margin guidance at 14.8% to 15.3% and free cash flow forecast at $500 million to $550 million. This gap between top-line improvement and bottom-line stagnation underscores a key investor concern: the recovery is driven by lower-margin distribution, not higher-margin products.
The company's VWR Distribution & Services segment, which accounts for 73.3% of revenue, posted organic growth of 1.7% with an adjusted operating margin of 10.2%. In contrast, the Bioscience & Medtech Products segment, representing 26.7% of revenue, saw organic sales decline 5.6%, though its adjusted operating margin was a healthier 26.0%. This unfavorable mix weighed on overall profitability, with gross margin falling 120 basis points to 31.7% and adjusted EBITDA margin dropping 160 basis points to 15.0%.
Management attributed the margin pressure to product mix, inflation, and lower volumes. Chief Executive Emmanuel Ligner noted that VWR returned to organic growth "more quickly than we anticipated," driven by controlled-environment consumables and specialty procurement. However, lower laboratory-consumables sales partially offset that growth, while Fluid Handling and NuSil products dragged on the Bioscience division.
Cash generation provided some support, with free cash flow rising to $142.8 million from $125.4 million in the prior-year quarter. Avantor used $112.1 million to repay debt, and adjusted net leverage ended the quarter at 3.3 times. However, first-half free cash flow fell 19% to $168 million due to lower operating cash and higher capital spending, leaving the full-year target unchanged.
The stock's move was company-specific, as peers Thermo Fisher Scientific (NYSE:TMO) slipped 0.5% and Danaher (NYSE:DHR) was nearly flat. Risks remain, particularly the high-margin Bioscience business, which has not stabilized. Additionally, VWR's estimated fair value exceeded its carrying value by only 5.5% at March 31, with about $2.8 billion of goodwill on the books. Avantor warned that weaker forecasts could trigger a material non-cash impairment charge.
Looking ahead, the key test for Avantor is sustaining growth in VWR while stabilizing the Bioscience segment before a broader margin recovery can materialize. The market will be watching closely to see if the company can translate its top-line momentum into improved profitability.
